Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

Newest Omicron subvariants can evade boosters, antibody therapies

Why omicron is more infectious than other coronavirus variants

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6

SARS-CoV-2 Study Forecasts Emergence of Immune Escape Variants

Omicron may not evade all monoclonal antibodies, lab study suggests, ET HealthWorld

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic - ScienceDirect

Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method

How monoclonal antibodies work against omicron variant - ABC News

Omicron variant evolution on vaccines and monoclonal antibodies

Omicron may sideline two leading drugs against COVID-19

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies - eBioMedicine